The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.51

Today's change+0.01 +0.29%
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $3.51

Today's change+0.01 +0.29%
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.

PDL BioPharma Inc Hits New 100-day High

PDL BioPharma Inc closed up Monday by (U.S.)$0.01 or 0.29% to (U.S.)$3.51 and setting a new 100-day high. Over the last five days, shares are unchanged, but have gained 65.57% over the last year to date. This security has underperformed the S&P 500 by 8.37% during the last year.

Key company metrics

  • Open(U.S.) $3.50
  • Previous close(U.S.) $3.50
  • High(U.S.) $3.55
  • Low(U.S.) $3.46
  • Bid / Ask(U.S.) $3.30 / (U.S.) $3.75
  • YTD % change+65.57%
  • Volume1,772,012
  • Average volume (10-day)1,695,535
  • Average volume (1-month)1,812,979
  • Average volume (3-month)1,748,188
  • 52-week range(U.S.) $1.93 to (U.S.) $3.77
  • Beta0.57
  • Trailing P/E7.76×
  • P/E 1 year forward5.74×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.45
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+23.03%

Based on its net profit margin of 23.03%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.01%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue144456654
Total other revenue--------
Total revenue144456654
Gross profit1394362--
Total cost of revenue534--
Total operating expense25277721
Selling / general / administrative15151310
Research & development4222
Depreciation / amortization6666
Interest expense (income), net operating--------
Unusual expense (income)-6--571
Other operating expenses, total11-62
Operating income11919-1033
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax11414-1528
Income after tax607-1014
Income tax, total547-414
Net income607-1014
Total adjustments to net income--------
Net income before extra. items607-1014
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items607-1014
Inc. avail. to common incl. extra. items607-1014
Diluted net income607-1014
Dilution adjustment--------
Diluted weighted average shares156164164164
Diluted EPS excluding extraordinary itemsvalue per share0.390.04-0.060.08
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.370.040.160.09